Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

NCT03989713 is registered in ClinicalTrials.gov with Prof. Dr. Richard F Schlenk as lead sponsor.

NCT NCT03989713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03989713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
Lead sponsor
Prof. Dr. Richard F Schlenk
Phase
Phase 2
Overall status
Terminated
Start date
July 17, 2020
Completion date
September 11, 2022
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml according to who 2016 classification (except acute promyelocytic leukemia) and (refractory to induction therapy or relapsed after first line treatment)